Regulatory glossary

FDA Warning Letter Response: Deadlines, Content, Close-Out

A Warning Letter is FDA's written statement that it considers a company in violation, naming the specific regulations and the conduct that breached them. It is issued after an inspection classified OAI, official action indicated, or on other evidence such as a label review or an import examination.

It is a step up from a Form 483 in three ways. It comes from the centre or district rather than an individual investigator, it cites regulations rather than observations, and it is published on FDA's website.

The deadline

Warning Letters state the response deadline on their face, ordinarily 15 working days from receipt. The letter is specific; read it rather than assuming the standard period.

Unlike a 483, the letter usually names a person and an address for the reply and asks for particular things. Answer what it asks for, in the form it asks for.

What the response must contain

The letter almost always requires three things, and a response that provides only the first is the most common failure mode.

• Corrections already made, with documentary evidence attached.
• A corrective action plan for what is not yet done, with dates.
• Steps to prevent recurrence, which is the systemic part.

Beyond that:

Address every violation. The letter is numbered. Answer in its numbering.

Do not confine yourself to the examples. Warning Letters routinely say the listed violations are not intended as an all-inclusive list and that you are responsible for investigating and determining the causes. A response scoped only to the named batches or products misses the question.

Bring evidence, not assurance. Revised procedures, training records, validation reports, completed investigations. A promise unaccompanied by a document is the weakest thing you can send.

If you disagree, include your reasoning and supporting data. The letter usually invites exactly this.

It is public from the day it posts

FDA publishes Warning Letters, and this is often the part that hurts first. The letter is found by customers, investors, partners performing diligence, and plaintiffs' counsel. For a company in a financing or an acquisition, a live Warning Letter changes the conversation.

That publication is also why the response matters beyond FDA. What you commit to becomes the thing you are measured against by everyone reading.

Close-out

FDA may issue a close-out letter once it has verified that the violations have been addressed, ordinarily after a follow-up inspection confirms the corrections. Close-out letters are also published.

A close-out is not automatic and not quick. It requires FDA to be satisfied that the corrective actions were completed, which for site-wide quality system findings usually means a re-inspection.

If it escalates

Where a company does not correct, the available actions include seizure, injunction, consent decree of permanent injunction, import alert for foreign sites, and for devices, withholding of new clearances or approvals while the quality system is out of compliance.

A consent decree is the outcome to avoid. It brings court supervision, a third-party expert, and often payments tied to milestones, and companies have operated under them for years.